Ferreira, J. P., Duarte, K., Graves, T. L., Zile, M. R., Abraham, W. T., Weaver, F. A., … Zannad, F. (2016). Natriuretic Peptides, 6-Min Walk Test, and Quality-of-Life Questionnaires as Clinically Meaningful Endpoints in HF Trials. Journal of the American College of Cardiology, 68(24), 2690–2707. https://doi.org/10.1016/j.jacc.2016.09.936

Ferreira, João Pedro, Kevin Duarte, Todd L. Graves, Michael R. Zile, William T. Abraham, Fred A. Weaver, JoAnn Lindenfeld, and Faiez Zannad. “Natriuretic Peptides, 6-Min Walk Test, and Quality-of-Life Questionnaires as Clinically Meaningful Endpoints in HF Trials.” Journal of the American College of Cardiology 68, no. 24 (December 2016): 2690–2707. https://doi.org/10.1016/j.jacc.2016.09.936.

Ferreira JP, Duarte K, Graves TL, Zile MR, Abraham WT, Weaver FA, et al. Natriuretic Peptides, 6-Min Walk Test, and Quality-of-Life Questionnaires as Clinically Meaningful Endpoints in HF Trials. Journal of the American College of Cardiology. 2016 Dec;68(24):2690–707.

Ferreira, João Pedro, et al. “Natriuretic Peptides, 6-Min Walk Test, and Quality-of-Life Questionnaires as Clinically Meaningful Endpoints in HF Trials.” Journal of the American College of Cardiology, vol. 68, no. 24, Elsevier BV, Dec. 2016, pp. 2690–707. Crossref, doi:10.1016/j.jacc.2016.09.936.

Ferreira JP, Duarte K, Graves TL, Zile MR, Abraham WT, Weaver FA, Lindenfeld J, Zannad F. Natriuretic Peptides, 6-Min Walk Test, and Quality-of-Life Questionnaires as Clinically Meaningful Endpoints in HF Trials. Journal of the American College of Cardiology. Elsevier BV; 2016 Dec;68(24):2690–2707.